Xeris Pharmaceuticals to Announce Fourth Quarter and Full Year 2019 Financial Results and Host Conference Call on March 11, 2020
27 févr. 2020 16h05 HE
|
Xeris Pharmaceuticals, Inc.
CHICAGO, Feb. 27, 2020 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and...
Xeris Pharmaceuticals Announces Pricing of Public Offering of Shares of Common Stock
11 févr. 2020 19h06 HE
|
Xeris Pharmaceuticals, Inc.
CHICAGO, Feb. 11, 2020 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize...
Xeris Pharmaceuticals Announces Proposed Public Offering of 6,000,000 Shares of Common Stock
10 févr. 2020 16h06 HE
|
Xeris Pharmaceuticals, Inc.
CHICAGO, Feb. 10, 2020 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize...
Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
27 déc. 2019 16h05 HE
|
Xeris Pharmaceuticals, Inc.
CHICAGO, Dec. 27, 2019 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize...
Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
29 nov. 2019 13h05 HE
|
Xeris Pharmaceuticals, Inc.
CHICAGO, Nov. 29, 2019 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize...
Xeris Pharmaceuticals Provides a Business Update During Recent Investor Conference
21 nov. 2019 06h00 HE
|
Xeris Pharmaceuticals, Inc.
MAA submitted to EMA of liquid stable glucagon for severe hypoglycemiaGVOKE™ PFS launch underwayGVOKE HypoPen™ expected to launch July 2020CHI program shifts to Expanded AccessHAAF program...
Xeris Pharmaceuticals Reports Third Quarter 2019 Financial Results and Highlights
07 nov. 2019 08h00 HE
|
Xeris Pharmaceuticals, Inc.
Gvoke™ (glucagon injection) pre-filled syringe (PFS) - now available by prescription MAA for ready-to-use glucagon on track for submission to EMA by year-end Data from three Phase 2 studies expected...
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
01 nov. 2019 16h05 HE
|
Xeris Pharmaceuticals, Inc.
CHICAGO, Nov. 01, 2019 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize...
Xeris Pharmaceuticals Appoints Mark Thierer to Board of Directors
01 oct. 2019 08h00 HE
|
Xeris Pharmaceuticals, Inc.
CHICAGO, Oct. 01, 2019 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and...
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
27 sept. 2019 16h05 HE
|
Xeris Pharmaceuticals, Inc.
CHICAGO, Sept. 27, 2019 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize...